



NDA 19-555/S-008

NDA 19-555/S-016

Schering Corporation
Attention: Joseph F. Lamendola, Ph.D.
Vice President, U.S. Regulatory Affairs
2000 Galloping Hill Road
Kenilworth, New Jersey 07033

Dear Dr. Lamendola:

Please refer to your supplemental new drug applications dated July 31, 1992, received August 7, 1992, and October 4, 2000, received October 5, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for DIPROLENE[®] AF (betamethasone dipropionate) Cream, 0.05%.

We acknowledge receipt of your submissions dated June 16, and September 5, 1995; March 21, April 8, and June 11, 1997; February 16, March 27, May 31, June 18, July 27, August 2, and September 25 (2) and 28 (facsimile), 2001.

These supplemental new drug applications provide for labeling revisions. Specifically, S-016 provides for labeling revisions based on the results of pediatric safety studies conducted with DIPROLENE[®] AF Cream in patients with atopic dermatitis, 12 years of age and younger, and supersedes S-008.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, immediate container and carton labels).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplements NDA 19-555/S-016; NDA 19-555/S-008." Approval of this submission by FDA is not required before the labeling is used.

We acknowledge your commitment specified in the facsimile of your letter dated September 28, 2001, to implement the enclosed labeling within 3 months of approval.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have fulfilled the pediatric study requirement at this time.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Olga I. Cintron, R.Ph., Project Manager, at (301) 827-2020.

Sincerely,

{See appended electronic signature page}

Jonathan K. Wilkin, M.D.
Director
Division of Dermatologic & Dental Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure